

37. *(Currently amended)* The composition of claim 31, wherein the cell is histocompatibly identical to the subject human.
38. *(Currently amended)* The composition of claim 31, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the tumor-associated antigen in the composition is ~~effective in treating~~ a neoplastic disease or eliciting an anti-tumor immunological response in the subject human.
39. *(Currently amended)* The composition of claim 38, wherein the tumor-associated antigen is obtained from a cell autologous to the subject human.
-
40. *(Previously added)* The composition of claim 38, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.
-
41. *(Currently amended)* The composition of claim 38, comprising a combination of:
a) the cell expressing the membrane-associated cytokine; and
b) a tumor cell autologous to the subject human;
wherein the combination is ~~effective in treating~~ a neoplastic disease or eliciting an anti-tumor immunological response in the subject human.
42. *(Currently amended)* The composition of claim 41, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the subject human.
-
43. *(Previously added)* The composition of claim 41, wherein the tumor cell is a glioma, a glioblastoma, a gliosarcoma, an astrocytoma, or an ovarian cancer cell.
-
44. *(Currently amended)* The composition of claim 41, wherein the tumor cell ~~is inactivated~~ has been inactivated by irradiation.
45. *(Currently amended)* The composition of claim 31, wherein the cell expressing the membrane-associated cytokine ~~is inactivated~~ has been inactivated by irradiation.

46. *(Previously added)* The composition of claim 31, wherein the cell produces a secreted cytokine in addition to the cytokine stably associated in the outer membrane.
47. *(Previously added)* The composition of claim 31, wherein a majority of the cytokine produced by the cell is present on the outer membrane of the cell.
-
48. *(Currently amended)* The composition of claim 38, wherein the cytokine is selected from ~~the group consisting of~~ IL-4, GM-CSF, IL-2, TNF- α , and M-CSF.
49. *(Currently amended)* A composition comprising a tumor associated antigen and a population of cells expressing a transmembrane cytokine wherein the cells have been inactivated to prevent proliferation, and at a level sufficient to stimulate wherein the composition is effective in stimulating an immune response to the tumor associated antigen.
50. *(Currently amended)* A unit dose of the composition according to claim 31, wherein the number of cells in the composition is at least about 5×10^6 but not more than about 2×10^8 .
-
51. *(Canceled)*
52. *(Previously added)* The composition of claim 31, wherein the cytokine naturally occurs as a membrane cytokine.
53. *(Previously added)* The composition of claim 31, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.
54. *(Previously added)* The composition of claim 31, wherein the cell has been transduced with a retroviral expression vector, or is the progeny of such a cell.

55. *(Previously added)* A method for producing the composition of claim 31, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.
56. *(Previously added)* The method of claim 55, wherein the expression vector is a retroviral vector.

b6 57. *(Currently amended)* The method of claim 55, wherein the cytokine is selected from the ~~group consisting of~~ IL-4, GM-CSF, IL-2, TNF- α , and M-CSF.

58. *(Previously added)* The method of claim 55, wherein the cytokine is expressed under control of a cytomegalovirus (CMV) promoter.

59. *(Currently amended)* The method of claim 55, wherein the cell is from a cancer of the same tissue type as a tumor in the ~~subject~~ human.

b7 60. *(Currently amended)* The method of claim 55, wherein the cell is allogeneic to the ~~subject~~ human.

61. *(Currently amended)* The method of claim 55, wherein the cell is histocompatibly identical to the ~~subject~~ human.

62. *(Previously added)* A method for producing the composition of claim 38, comprising transducing a cell with an expression vector encoding the membrane-associated cytokine, and providing the transduced cell in combination with the ~~tumor-associated antigen~~.

63. *(New)* The method of claim 55, further comprising inactivating the cell to prevent proliferation.

b8 64. *(New)* The method of claim 55, further comprising irradiating the cell.

65. *(New)* The composition of claim 31, wherein the cytokine is IL-4.

66. (New) The composition of claim 31, wherein the cytokine is GM-CSF.

✓ 67. (New) The composition of claim 31, wherein the cytokine is M-CSF.

✓ 68. (New) A pharmaceutical composition ~~(effective in treating)~~ a neoplastic disease or eliciting an anti-tumor immunological response, comprising:

- a) a human cell expressing a cytokine from a recombinant polynucleotide; and
- b) a pharmaceutical excipient;

wherein the cytokine is stably associated in the cell outer membrane, and

wherein the composition has been formulated for administration to an allogeneic human subject.

✓ 69. (New) The composition of claim 68, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- α , and M-CSF.

✓ 70. (New) The composition of claim 68, wherein the cell is a cancer cell.

71. (New) The composition of claim 68, wherein the cell is from a tumor of the same tissue type as a tumor in the human.

✓ 72. (New) The composition of claim 68, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the ~~tumor-associated antigen~~ in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.

73. (New) The composition of claim 72, wherein the ~~tumor-associated antigen~~ is obtained from a cell autologous to the human.

✓ 74. (New) The composition of claim 72, wherein the ~~tumor-associated antigen~~ is expressed by the same cells expressing the membrane-associated cytokine.

75. (New) The composition of claim 72, comprising a combination of:
- a) the cell expressing the membrane-associated cytokine; and
 - b) a tumor cell autologous to the human;
- wherein the combination is ~~effective in treating~~ a neoplastic disease or eliciting an anti-tumor immunological response in the human.
76. (New) The composition of claim 75, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the human.
77. (New) The composition of claim 68, wherein the cell expressing the membrane-associated cytokine has been ~~inactivated~~ by irradiation.
78. (New) A method for producing the composition of claim 68, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.
79. (New) The method of claim 78, wherein the expression vector is a retroviral vector.
80. (New) The method of claim 78, further comprising ~~inactivating~~ the cell to prevent proliferation.
81. (New) The method of claim 78, further comprising irradiating the cell.
-